A Vertex Pharmaceuticals partnership with CRISPR Therapeutics to test a genetically engineered drug in patients as a treatment for sickle cell disease has been dealt a setback.
The FDA placed a clinical hold on the application that Vertex (NASDAQ: VRTX) and CRISPR Therapeutics (NASDAQ: CRSP) submitted to start human studies, the companies announced Wednesday after the market close.
In a prepared statement, Vertex and CRISPR Therapeutics said that the clinical hold on CTX001 stemmed from “the resolution of certain questions that will be provided by the FDA as part of its review” of the investigational new drug application. The… Read more »
UNDERWRITERS AND PARTNERS